Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
EuroBiotech Report—Teva dumps laquinimod, Gilead-Galapagos, GV-Evox, Abivax data and ProQR | Fierce Biotech
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod - Wikipedia
Laquinimod - an overview | ScienceDirect Topics
Active Biotech regains rights of laquinimod from Teva
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Patient enrollment in Phase III trial of laquinimod completed
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Meet the Compound: Laquinimod – HD Insights
Active Biotech and Teva together in a Phase II clinical trial against Huntington's disease - Labiotech.eu
AhR activators - friend or foe? - Hypha Discovery Blogs
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
AhR activators - friend or foe? - Hypha Discovery Blogs
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
laquinimod
Teva drops development of laquinimod - PharmaTimes
